CrossRoads Pharmaceuticals

CrossRoads's mission is to develop Zinc-alpha2-glycoprotein (ZAG) as a safe, natural, and highly effective treatment for obesity and type II diabetes.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Santa Monica, CA, USA
  • Currency USD
  • Founded May 2017
  • Employees 2
  • Incorporation Type C-corp
  • Website http://In development

Company Summary

CrossRoads seeks to expand upon compelling pre-clinical studies that demonstrate ZAG to be effective in both oral and intravenous forms. We seek to raise $1 million for R&D which will be used to generate novel intellectual property. Later funding will be used to conduct FDA approved pre-clinical studies and enter Phase 1 trials. We are concurrently seeking a major pharmaceutical partnership to assist with financing through Phase 3 trials.

Team

  • John Neely
    CEO

    Dr. John C. Neely MD graduated from the Joan C Edwards School of Medicine at Marshall University. He completed his internal medicine residency at LSU Shreveport and emergency medicine fellowship at Methodist Hospital in Memphis, Tennessee. Dr. Neely independently discovered ZAG in 2012. He has ten years’ clinical experience and has published extensively.

  • Kenneth Laderman, Ph.D.
    Chief Scientific Officer

    Dr. Laderman holds a Ph.D. in Cell Biology from Johns Hopkins, and received postdoctoral fellowships from Caltech and UCLA. He has a research faculty appointment at Caltech, and eighteen years of biotech experience with pharmaceutical companies, including Bausch & Lomb. Dr. Laderman holds 3 patents and has exact domain expertise in cell culture, protein purification, FDA compliant GLP/GMP operations, and biologic manufacturing.

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free